Has Leora Horn received payments from drug or device companies?

Yes. Drug and device makers reported $97,754 in general payments to Leora Horn across 64 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Leora Horn did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Leora Horn come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Leora Horn

Medical Oncology · Nashville, TNNPI 1487881041

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $80,305 of the $97,754 with a category attached, or 82.1%. 13 manufacturers reported payments, led by AstraZeneca at 24.9% of the total. Reporting peaked in 2019 at $60,580 and has fallen 95.5% since, to $2,740 in 2021.

$97,754in general payments, 2019–2025

Across 64 payments — averaging $1527.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$24K
Merck$19K
Pfizer$11K
EMD Serono, Inc.$9K
F. Hoffmann-la Roche AG$9K
Hoffmann-la Roche Limited$8K
plus $19K from 7 others

$2,509,415in research payments, 2019–2025

Across 442 payments — averaging $5677.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Takeda Pharmaceuticals U.S.A., Inc.$464K
Boehringer Ingelheim Pharma GmbH & Co.kg$451K
AstraZeneca$310K
E.r. Squibb & Sons, L.L.C.$255K
EMD Serono, Inc.$245K
Incyte Corporation$219K
plus $565K from 12 others

What the payments were for

Consulting fees$80,30582%
Speaking & faculty fees$8,4639%
Travel & lodging$4,5835%
Food & beverage$4,4035%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	17	$24,384
Merck	10	$18,679
Pfizer	7	$10,577
EMD Serono, Inc.	2	$8,625
F. Hoffmann-la Roche AG	8	$8,523
Hoffmann-la Roche Limited	2	$7,693
Incyte Corporation	5	$4,989
Genentech USA, Inc.	4	$4,856
Astrazeneca UK Limited	2	$3,350
Amgen	2	$3,300
Bristol Myers Squibb	2	$2,704
Astrazeneca AB	2	$51
Genentech, Inc.	1	$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

TECENTRIQ$16,566
TAGRISSO$13,280
IMFINZI$9,474
Alecensa$4,803
ROZLYTREK$4,803
BAVENCIO$4,000
Tepotinib$2,625

How this compares

$97,754 in reported general payments places this provider in the 85th percentile of 101 medical oncology providers in Tennessee.

See all medical oncology providers in Tennessee →

Other medical oncology in Nashville

William PaoNashville$838K
Dana ThompsonNashville$339K
Robert RamirezNashville$321K
Mace RothenbergNashville$318K
Melissa JohnsonNashville$290K
Cathy EngNashville$231K
David SpigelNashville$167K
Michael GibsonNashville$141K
Jordan BerlinNashville$120K
Vandana AbramsonNashville$98K

See the full list for Tennessee →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →